IL6 and juvenile Huntington disease: In a 3-nitropropionic acid animal model of Huntington’s disease (HD), RES derivatives delayed the onset and reduced the severity of HD-like symptoms, improved locomotor activity, and protected against weight loss, with simultaneous enhancement of superoxide dismutase 2 (SOD2) expression in brain tissue and a decrease in circulating levels of interleukin-6 (IL-6), respectively [51].